81470-51-1

Basic information

• Product Name: Z-Pyr-OtBu
• Synonyms: 1-Benzyl 2-(2-methyl-2-propanyl) (2S)-5-oxo-1,2-pyrrolidinedicarboxylate;1,2-Pyrrolidinedicarboxylic acid, 5-oxo-, 2-(1,1-dimethylethyl)1-(phenylmethyl) ester, (S)-;Z-Pyr-OtBu
• CAS NO: 81470-51-1
• Molecular Formula: C₁₇H₂₁NO₅
• Molecular Weight: 319.35234
• Mol File: 81470-51-1.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Z-Pyr-OtBu(CAS DataBase Reference)
• NIST Chemistry Reference: Z-Pyr-OtBu(81470-51-1)
• EPA Substance Registry System: Z-Pyr-OtBu(81470-51-1)

Safety Data

• Hazardous Substances Data: 81470-51-1(Hazardous Substances Data)

Usage

General Description

Z-Pyr-OtBu is a chemical compound that is commonly used as a building block in the synthesis of various pharmaceuticals and organic materials. It features a pyridine ring with an appended tert-butyl ester functional group, which provides stability and protection to reactive intermediates during chemical reactions. Z-Pyr-OtBu is known for its versatility in organic synthesis, particularly in the preparation of complex molecules for drug development and materials science. Due to its unique structure and reactivity, Z-Pyr-OtBu has found broad applications in the laboratory setting and has contributed to advancements in the fields of chemistry and medicine.

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 32159-21-0 Cbz-L-pGlu-OH 
• 57732-63-5 1-tert-butyl 5-methyl (2S)-2-{[(benzyloxy)carbonyl]amino}pentanedioate 
• 56-86-0 L-glutamic acid 
• 501-53-1 benzyl chloroformate 
• 35418-16-7 L-t-butyl pyroglutamate 
• 115-11-7 isobutene 
• 75-65-0 tert-butyl alcohol 
• 16881-39-3 (S)-2-tert-butyl-1-benzylpyrrolidine-1,2-dicarboxylate 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 
• 2398-37-0 3-methoxyphenyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 31139-36-3 dibenzyl dicarbonate 

Downstream Products

• 127949-79-5 t-butyl (2S)-1-benzyloxycarbonyl-4-(1-hydroxypropyl)pyroglutamate 
• 1033713-89-1 1-benzyl 2-tert-butyl (2S)-5-methoxypyrrolidine-1,2-dicarboxylate 
• 1033709-22-6 (5R)-1-{[(5R,6S)-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]carbonyl}-5-ethyl-L-proline 
• 1033714-59-8 (5R)-1-[(benzyloxy)carbonyl]-5-methyl-L-proline 
• 1033713-91-5 (5R)-1-[(benzyloxy)carbonyl]-5-ethyl-L-proline 
• 1033714-79-2 benzyl (2S,5R)-2-{[(3S)-3,4-dimethylpiperazin-1-yl]carbonyl}-5-methylpyrrolidine-1-carboxylate 
• 1033714-69-0 benzyl (2S,5R)-2-{[(3R)-3,4-dimethylpiperazin-1-yl]carbonyl}-5-ethylpyrrolidine-1-carboxylate 
• 1443977-66-9 (5R)-1-{[(5R,6S)-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]carbonyl}-N,N,5-trimethyl-L-prolinamide 
• 1033708-88-1 (5R)-1-{[(5R,6S)-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazol-2-yl]carbonyl}-5-ethyl-N,N-dimethyl-L-prolinamide 
• 1443977-67-0 (5R,6S)-5,6-bis(4-chlorophenyl)-2-({(2R,5S)-2-methyl-5-[(4-methylpiperazin-1-yl)carbonyl]pyrrolidin-1-yl}carbonyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole 
• 1443977-68-1 (5R,6S)-2-({(2S,5R)-2-[(4-acetylpiperazin-1-yl)carbonyl]-5-methylpyrrolidin-1-yl}carbonyl)-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole 
• 1033709-23-7 (5R,6S)-5,6-bis(4-chlorophenyl)-2-({(2R,5S)-2-ethyl-5-[(4-methylpiperazin-1-yl)carbonyl]pyrrolidin-1-yl}carbonyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole 
• 1033709-30-6 (5R,6S)-2-({(2S,5R)-2-[(4-acetylpiperazin-1-yl)carbonyl]-5-ethylpyrrolidin-1-yl}carbonyl)-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole 
• 1443977-69-2 (5R,6S)-5,6-bis(4-chlorophenyl)-2-{[(2R,5S)-2-ethyl-5-(morpholin-4-ylcarbonyl)pyrrolidin-1-yl]carbonyl}-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole 

Relevant articles and documents

The synthesis of γ-Substituted Glutamic Acids via a Glutamic Acid γ-Enolate Synthon.

Treatment of α-t-butyl γ-methyl N-Z-glutamate (4) with lithium hexamethyldisilazide results in the regiospecific formation of the γ-anion, which reacts with electrophiles to give γ-substituted glutamic acid derivatives.

The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors

HCV NS5A inhibitors are the backbone of directly acting antiviral treatments against the hepatitis C virus (HCV). While these therapies are generally highly curative, they are less effective in some specific HCV patient populations. In the search for broader-acting HCV NS5A inhibitors that address these needs, we explored conformational restrictions imposed by the [7,5]-azabicyclic lactam moiety incorporated into daclatasvir (1) and related HCV NS5A inhibitors. Unexpectedly, compound 5 was identified as a potent HCV genotype 1a and 1b inhibitor. Molecular modeling of 5 bound to HCV genotype 1a suggested that the use of the conformationally restricted lactam moiety might have resulted in reorientation of its N-terminal carbamate to expose a new interaction with the NS5A pocket located between amino acids P97 and Y93, which was not easily accessible to 1. The results also suggest new chemistry directions that exploit the interactions with the P97-Y93 site toward new and potentially improved HCV NS5A inhibitors.

DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.